Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
Authors:
- Monica BenvenutoMonica Benvenuto
- Sara CiuffaSCSara Ciuffa
- Chiara FocaccettiChiara Focaccetti
- Diego SbardellaDSDiego Sbardella
- Sara FaziSFSara Fazi
- Manuel ScimecaManuel Scimeca
- Grazia Raffaella TundoGTGrazia Raffaella Tundo
- Giovanni BarillariGBGiovanni Barillari
- Maria SegniMSMaria Segni
- Elena BonannoElena Bonanno
- Vittorio ManzariVMVittorio Manzari
- Andrea ModestiAMAndrea Modesti
Open Access
- 24 September 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-23
Abstract
Head and neck cancer (HNC) has frequently an aggressive course for the development of resistance to standard chemotherapy. Thus, the use of innovative therapeutic drugs is being assessed. Bortezomib is a proteasome inhibitor with anticancer effects. In vitro antitumoral activity of Bortezomib was investigated employing human tongue (SCC-15, CAL-27), pharynx (FaDu), salivary gland (A-253) cancer cell lines and a murine cell line (SALTO-5) originated from a salivary gland adenocarcinoma arising in BALB-neuT male mice transgenic for the oncogene neu. Bortezomib inhibited cell proliferation, triggered apoptosis, modulated the expression and activation of pro-survival signaling transduction pathways proteins activated by ErbB receptors and inhibited proteasome activity in vitro. Intraperitoneal administration of Bortezomib delayed tumor growth of SALTO-5 cells transplanted in BALB-neuT mice, protracted mice survival and adjusted tumor microenvironment by increasing tumor-infiltrating immune cells (CD4+ and CD8+ T cells, B lymphocytes, macrophages, and Natural Killer cells) and by decreasing vessels density. In addition, Bortezomib modified the expression of proteasome structural subunits in transplanted SALTO-5 cells. Our findings further support the use of Bortezomib for the treatment of HNC and reveal its ineffectiveness in counteracting the activation of deregulated specific signaling pathways in HNC cell lines when resistance to proteasome inhibition is developed.Keywords
Funding Information
- University of Rome “Tor Vergata” (CUP: E81I18000330005)
This publication has 111 references indexed in Scilit:
- Phase II 2‐arm trial of the proteasome inhibitor, PS‐341 (bortezomib) in combination with irinotecan or PS‐341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology GroupHead & Neck, 2012
- Proteasome Inhibitors: An Expanding Army Attacking a Unique TargetChemistry & Biology, 2012
- Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activationCancer Letters, 2012
- A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neckCancer, 2011
- Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic miceCancer Immunology, Immunotherapy, 2010
- Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinomaAnnals of Oncology, 2009
- Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptorBritish Journal of Cancer, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist AntibodyJNCI: Journal of the National Cancer Institute, 2008
- ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997